We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+8.97%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
-$24.8M
(-0.89%)
Cap. Flow
-$295M
Cap. Flow
% of AUM
-10.7%
Top 10 Holdings %
Top 10 Hldgs %
47.94%
Holding
172
New
14
Increased
31
Reduced
25
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$27.4M |
| 2 |
SHPG
Shire pic
SHPG
|
+$25.4M |
| 3 |
Illumina
ILMN
|
+$22.1M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$19.9M |
| 5 |
HCA Healthcare
HCA
|
+$14.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$72.3M |
| 2 |
Alkermes
ALKS
|
+$45.9M |
| 3 |
AET
Aetna Inc
AET
|
+$36.3M |
| 4 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$23M |
| 5 |
AKRX
Akorn Inc
AKRX
|
+$22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.47% |
| 2 | Real Estate | 3.59% |
| 3 | Financials | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALR
51
DELISTED
Alere Inc
ALR
| $11.6M | 0.42% |
297,901
| – | – |
|
52
Ardelyx
ARDX
$1.25B
| $11.6M | 0.42% |
639,370
-900
| -0.1% | -$16.8K |
|
53
Stryker
SYK
$133B
| $11.5M | 0.42% |
123,940
| – | – |
|
54
GSK
GSK
$104B
| $11.5M | 0.42% |
228,000
| – | – |
|
55
Zimmer Biomet
ZBH
$18.4B
| $10.5M | 0.38% |
105,369
| – | – |
|
|
LTC
56
LTC Properties
LTC
$2.06B
| $10.2M | 0.37% |
236,618
| – | – |
|
|
ITCI
57
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.1M | 0.37% |
187,800
+37,800
| +25% | +$1.91M |
|
|
DHC
58
Diversified Healthcare Trust
DHC
$2.17B
| $9.95M | 0.36% |
670,504
-6,035
| -0.9% | -$90.2K |
|
59
Ultragenyx Pharmaceutical
RARE
$2.56B
| $9.92M | 0.36% |
88,400
| – | – |
|
60
Idexx Laboratories
IDXX
$44.1B
| $9.65M | 0.35% |
132,352
| – | – |
|
61
Medtronic
MDT
$110B
| $9.56M | 0.35% |
124,344
-82,700
| -40% | -$6.23M |
|
62
Natera
NTRA
$38.6B
| $9.53M | 0.35% |
882,358
+68,058
| +8% | +$647K |
|
63
Sabra Healthcare REIT
SBRA
$5.38B
| $9.23M | 0.33% |
456,190
| – | – |
|
64
Icon
ICLR
$12.8B
| $8.93M | 0.32% |
114,900
+42,900
| +60% | +$3.06M |
|
|
PVLA
65
Palvella Therapeutics
PVLA
$2.15B
| $8.81M | 0.32% |
48,102
| – | – |
|
66
Universal Health Services
UHS
$9.88B
| $8.4M | 0.3% |
+70,300
| New | +$8.59M |
|
67
Community Health Systems
CYH
$391M
| $8.08M | 0.29% |
368,411
+114,829
| +45% | +$2.97M |
|
|
JUNO
68
DELISTED
Juno Therapeutics, Inc.
JUNO
| $8M | 0.29% |
182,000
| – | – |
|
69
Novartis
NVS
$301B
| $7.98M | 0.29% |
103,453
| – | – |
|
70
Centene
CNC
$30.1B
| $7.9M | 0.29% |
240,000
| – | – |
|
71
Eli Lilly
LLY
$1.03T
| $7.22M | 0.26% |
85,667
| – | – |
|
|
WCG
72
DELISTED
Wellcare Health Plans, Inc.
WCG
| $6.93M | 0.25% |
88,652
| – | – |
|
73
CytomX Therapeutics
CTMX
$714M
| $6.85M | 0.25% |
+328,059
| New | +$5.19M |
|
|
MACK
74
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $6.75M | 0.24% |
108,516
| – | – |
|
|
DVAX
75
DELISTED
Dynavax Technologies
DVAX
| $6.64M | 0.24% |
275,000
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, Tekla Capital Management held 172 positions worth $2.76B, down 0.89% from $2.78B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Tekla Capital Management withdrew a net $295M in Q4 2015, closing 39 positions and reducing 25 holdings. Its most notable exit was Aetna Inc, an estimated $36.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier, followed by Real Estate and Financials.
Against the trend, Tekla Capital Management opened a new position in Sanofi worth $13M.
- Tekla Capital Management's largest Q4 2015 buy was Sanofi: 305,000 shares worth $13M.
- Tekla Capital Management added most to Allergan plc in Q4 2015, an estimated $27.4M increase.
- Tekla Capital Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $72.3M.
- Tekla Capital Management fully exited Aetna Inc in Q4 2015, selling an estimated $36.3M.
- Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q4 2015.
- Tekla Capital Management opened 14 new positions and closed 39 in Q4 2015.
- Tekla Capital Management's portfolio value fell 0.89% quarter-over-quarter to $2.76B.
Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.